Daiichi Sankyo, Inc. is reorganizing its U.S. Commercial organization to transition from a maturing primary care product portfolio to a differentiated specialty portfolio including areas such as cardiovascular, pain management and oncology.  To reduce expenses, the company expects to eliminate 1,000 to 1,200 positions across the U.S. Commercial function located in Parsippany, NJ, as well as field-based sales and other positions throughout the country. This reorganization does not include U.S....